HOME >> BIOLOGY >> NEWS
Gene therapy offers new hope for treatment of peripheral neuropathy

SEATTLE, May 31 Researchers from the University of Pittsburgh School of Medicine report that they have successfully used gene therapy to block the pain response in an animal model of neuropathic pain, a type of chronic pain in people for which there are few effective treatments. These findings are being presented at the 10th annual meeting of the American Society of Gene Therapy, being held May 30 to June 3 at the Washington State Convention & Trade Center, Seattle.

Neuropathic pain is the result of damage to nerve fibers caused by injuries or diseases, such as diabetes and cancer. These damaged nerve fibers continue to send signals to pain centers in the brain even after the surrounding tissue has healed. Unfortunately, neuropathic pain often responds poorly to standard pain treatments and occasionally may get worse instead of better over time. For some people, it leads to serious, long-term disability and dependence on pain medications that have a variety of unwanted side effects, including addiction.

The Pitt research team, led by Joseph Glorioso, III, Ph.D., chair of the department of biochemistry and molecular genetics, University of Pittsburgh School of Medicine, used a genetically engineered herpes simplex virus (HSV) to deliver the gene for part of the human glycine receptor (GlyR), a receptor found primarily on the surface of nerve cells in the spinal cord and the lower brain but not in the nerves in the limbs, to the paws of rats. A group of control rats received only the HSV vector without the inserted gene. After the delivery of the therapeutic gene or empty vector (for the control group), the researchers injected the same paws of each rat with formalin, an irritant known to simulate the symptoms of a peripheral neuropathic pain at the site of injection. Following formalin injection, the rats were then given an injection of glycine to activate the GlyR receptor.

Both control and GlyR-HSV-infected rats showed a typical pa
'"/>

Contact: Jim Swyers
SwyersJP@upmc.edu
412-657-4957
University of Pittsburgh Schools of the Health Sciences
31-May-2007


Page: 1 2

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/23/2020)... (PRWEB) , ... August 21, 2020 , ... ... Rigaku Corporation has been published and is now available on the company’s ... X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. ...
(Date:8/21/2020)... ... August 19, 2020 , ... ... conference and expo uniting life science, data science, informatics and IT leaders goes ... “In this period of uncertainty and change, Bio-IT takes the leadership role of ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions its ... MediVet Biologics since its formation in 2016, the company is relaunching itself under the ... on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... life sciences industry, today announced the release of its signature product called ... Science Liaisons (MSLs) and other field medical professionals. , Beacon helps ...
(Date:7/18/2020)... DAYTON, Ohio (PRWEB) , ... July 16, 2020 ... ... clinical data solutions to aid in the early detection and prevention of high-burden ... partnership to enable US-based hospitals and healthcare organizations to utilize existing data in ...
Breaking Biology Technology:
Cached News: